No evidence to support use of vitamin C supplementation in cancer
the ONA take:
According to a new study published in the journal The Oncologist, researchers have found that there is no high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance efficacy or reduce toxicity of chemotherapy in patients with cancer.
For the systematic review, researchers from the Ottawa Hospital Cancer Centre Division of Medical Oncology in Ottawa, Ontario, Canada, sought to investigate whether supplemental ascorbate synergizes the anticancer effects of chemotherapy and reduces its toxicity.
Researchers identified 34 articles to be included in the study from Medline, EMBASE, and the Cochrane central register. Among those, there were five randomized controlled studies, 12 phase 1/2 studies, six observational trials, and 11 case reports.
The studies included a total of over 8,000 patients. Results showed no statistically significant improvements in overall survival or progression-free survival or reduced toxicity with supplemental ascorbate use compared with the control arm.
The authors note that high-quality placebo-controlled studies are needed to assess the effects of ascorbate on chemotherapy efficacy and toxicity in patients with cancer.
No high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance cancer treatment.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|